DBV Technologies: Two Regulatory Submissions Planned in 2026 for Viaskin Peanut Patch
DBV Technologies unveils its regulatory submission schedule for its flagship pediatric allergy treatment. The French biotech plans two biologics license applications (BLA) this year, respectively for children aged 4 to 7 years and toddlers aged 1 to 3 years, as well as the launch of a new Phase 2 study in infants aged 6 to 12 months.
A Focused Schedule of Regulatory Submissions
DBV Technologies sets a brisk pace for its flagship candidate, the VIASKIN Peanut patch. The company plans to file its first biologics license application in the first half of 2026 for children aged 4 to 7 years, followed by a second submission in the second half for the 1 to 3-year-old age group. This dual request covers an extension of the pediatric population allergic to peanuts, potentially broadening the accessible patient base. Daniel Tassé, CEO, emphasized an approach marked by 'extreme precision and determination' in product development.
A Groundbreaking Study Planned for Very Young Children
Beyond regulatory filings, DBV announces the initiation of the THRIVE trial, a Phase 2 study aimed at infants aged 6 to 12 months. This trial will assess the efficacy and safety of the VIASKIN Peanut patch to enable peanut consumption after at least three years of treatment. The study was announced last year at the American College of Asthma, Allergy, and Immunology congress. Its launch represents an extension of the treatment strategy to younger patients, thus covering the entire spectrum of pediatric ages allergic to peanuts.
Execution Challenges and Regulatory Visibility
These three milestones (two BLAs and a new study) position DBV Technologies at a pivotal phase of its development in 2026. The concentration of these major events in a single year will be decisive for the future commercial trajectory of the group.
